Major antibiotic partnership program reveals how to sustain drug development efforts
A five-year review of the AMR Accelerator, a nine-project collaboration to develop new antibiotics, shows that coordinated programs work—but only if organizations commit to long-term funding and infrastructure. As drug-resistant infections worsen, the study offers a blueprint for how pharma and governments can share costs and expertise to build sustainable antibiotic pipelines.
Originaltitel: The AMR Accelerator: from individual organizations to efficient antibiotic development partnerships
<p>The AMR Accelerator is an Innovative Medicines Initiative programme integrating nine projects with the shared goal of progressing the development of new antibiotics and building antimicrobial resistance research capability. Five years in, we reflect on the programme’s value, results and key challenge: ensuring the sustainability of assets, infrastructures and expertise.</p>